_PRIVATE_LIMITED.webp)
Stg Pharmagenerics Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 26-06-2024
- Paid Up Capital ₹ 5.00 M
as on 26-06-2024
- Company Age 7 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 10.00 Cr
as on 26-06-2024
- Revenue 207.01%
(FY 2023)
- Profit -2749.25%
(FY 2023)
- Ebitda -569.38%
(FY 2023)
- Net Worth -280.86%
(FY 2023)
- Total Assets -56.18%
(FY 2023)
About Stg Pharmagenerics
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 5.00 M.
The company currently has active open charges totaling ₹10.00 Cr.
Tarun Gupta and Rajesh Gupta serve as directors at the Company.
- CIN/LLPIN
U51909MH2017FTC291263
- Company No.
291263
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
15 Feb 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Stg Pharmagenerics?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Tarun Gupta  | Director | 15-Feb-2017 | Current |
Rajesh Gupta  | Whole-Time Director | 15-Feb-2017 | Current |
Financial Performance of Stg Pharmagenerics.
Stg Pharmagenerics Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 207.01% increase. The company also saw a substantial fall in profitability, with a 2749.25% decrease in profit. The company's net worth observed a substantial decline by a decrease of 280.86%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Stg Pharmagenerics?
In 2021, Stg Pharmagenerics had a promoter holding of 90.00% and a public holding of 10.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Urihk Pharmaceutical Private LimitedActive 7 years 24 daysTarun Gupta and Rajesh Gupta are mutual person
P K Pharmatech Private LimitedActive 25 years 6 monthsTarun Gupta and Rajesh Gupta are mutual person
Joint Force Pharmachem Private LimitedActive 12 years 7 monthsTarun Gupta and Rajesh Gupta are mutual person
- Serendipity Speciality Foods Private LimitedActive 3 years 11 months
Rajesh Gupta is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 27 Jun 2022 | ₹10.00 Cr | Open |
How Many Employees Work at Stg Pharmagenerics?
Unlock and access historical data on people associated with Stg Pharmagenerics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Stg Pharmagenerics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Stg Pharmagenerics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
